Design and Implementing Cancer Data Warehouse to Support Clinical Decisions

2017 ◽  
Author(s):  
Alaa Almansory ◽  
Hasan Adday ◽  
Taleb Obaid ◽  
Rabab Hameed
Keyword(s):  
Data Warehouse ◽  
Clinical Decisions ◽  
Cancer Data

Design and Implementing Cancer Data Warehouse to Support Clinical Decisions

2016 ◽  
Author(s):  
Alaa Khalaf Hamoud ◽  
Hasan Adday ◽  
Taleb Obaid ◽  
Rabab Abdllmajed Hameed
Keyword(s):  
Data Warehouse ◽  
Clinical Decisions ◽  
Cancer Data

scholarly journals Building a Lung and Ovarian Cancer Data Warehouse

2020 ◽  
Vol 26 (4) ◽  
pp. 303-310
Author(s):  
Canan Eren Atay ◽  
Georgia Garani
Keyword(s):  
Ovarian Cancer ◽  
Data Warehouse ◽  
Cancer Data ◽  
Ovarian Cancer Data

Encountering Incomplete Temporal Information in Clinical Data Warehouses

2020 ◽  
Vol 5 (1) ◽  
pp. 32-48 ◽  
Author(s):  
Georgia Garani ◽  
Canan Eren Atay
Keyword(s):  
Data Warehouse ◽  
Clinical Data ◽  
Data Repository ◽  
Test Results ◽  
Cancer Data ◽  
Clinical Data Warehouse ◽  
Laboratory Test Results ◽  
History Of ◽  
First Time ◽  
Complete History

A clinical data warehouse (CDW) can be an important tool for the purposes of analysis and critical decision making in the medical field. Such a data repository integrates heterogeneous health data, including clinical, treatment and diagnostic data and laboratory test results from a variety of sources. Accurate data need to be stored and processed in a CDW with adequate computation capabilities and thus, time plays a crucial factor. A slowly changing dimension (SCD) is a dimension that changes slowly over time, either gradually or intermittently. This article introduces a new SCD type, Type BTA, where both valid time and transaction time are supported for providing a complete history of the dimensional data. With Type BTA, the history of an object can be captured through the changes as reflected in the CDW. Consequently, for the first time, the full history of retroactive and post-active changes can be preserved in a CDW. Specifically, Type BTA is implemented for a Clinical Data Warehouse using real cancer data, for which the advantages of this methodology are demonstrated and advocated.

scholarly journals Crusade for Cancer Data: How a Non-SEER Site Populated the Virtual Data Warehouse Tumor Table

2017 ◽  
Vol 4 (3) ◽  
pp. 175-176
Author(s):  
Pamala A Pawloski ◽  
Jody Jackson ◽  
Amy Butani ◽  
Terese DeFor ◽  
Sheryl Kane
Keyword(s):  
Data Warehouse ◽  
Cancer Data ◽  
Virtual Data

Much Ado About Fried Chicken: Abetting Aspiration or Respecting Autonomy?

2019 ◽  
Vol 28 (3) ◽  
pp. 1356-1362
Author(s):  
Laurence Tan Lean Chin ◽  
Yu Jun Lim ◽  
Wan Ling Choo
Keyword(s):  
Palliative Care ◽  
End Of Life ◽  
Multidisciplinary Team ◽  
Biopsychosocial Model ◽  
Family Members ◽  
Clinical Decisions ◽  
Goals Of Care ◽  
Complex Needs ◽  
Aspiration Risk ◽  
Patient Centric

Purpose Palliative care is a philosophy of care that encompasses holistic, patient-centric care involving patients and their family members and loved ones. Palliative care patients often have complex needs. A common challenge in managing patients near their end of life is the complexity of navigating clinical decisions and finding achievable and realistic goals of care that are in line with the values and wishes of patients. This often results in differing opinions and conflicts within the multidisciplinary team. Conclusion This article describes a tool derived from the biopsychosocial model and the 4-quadrant ethical model. The authors describe the use of this tool in managing a patient who wishes to have fried chicken despite aspiration risk and how this tool was used to encourage discussions and reduce conflict and distress within the multidisciplinary team.

464: Is Obesity Associated with more Aggressive Prostate Cancer? (Data from Capsure)

2004 ◽  
Vol 171 (4S) ◽  
pp. 124-124 ◽  
Author(s):  
Christopher J. Kane ◽  
William W. Bassett ◽  
Natalia Sadetsky ◽  
Stephanie J. Silva ◽  
David J. Pasta ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Aggressive Prostate Cancer ◽  
Cancer Data

HER2 Expression in Gastric Cancer and Gastroesophageal Junction Cancer

2020 ◽  
Vol 22 (2) ◽  
pp. 79-82
Author(s):  
Md Azizur Rahman ◽  
Abdullah Md Abu Ayub Ansari ◽  
Kazi Mazharul Islam ◽  
Md Aminur Rahman ◽  
ABM Abdul Matin ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Carcinoma ◽  
Social Impact ◽  
Gastroesophageal Junction ◽  
Treatment Protocol ◽  
Armed Forces ◽  
Her2 Expression ◽  
Her2 Positive ◽  
Cancer Data ◽  
Her2 Positivity

Background: Carcinoma of the stomach is a major cause of cancer mortality worldwide. Due to social impact of gastric carcinoma (GC), there is a need to stratify patients into appropriate screening, surveillance and treatment programs. Although histopathology remains the most reliable and less expensive method, numerous efforts have been made to identify and validate novel biomarkers to accomplish the goals. In recent years, several molecules have been identified and tested for their clinical relevace in GC management. Among the biomarkers with the exception of HER2, none of the biomarkers is currently used in clinical practice, and some of them were described in single studies. Materials and Methods: This prospective type of observational study was performed in the Department of Surgery, Dhaka Medical College Hospital, Dhaka, 6 months from approval of protocol. Total 45 consecutive patients aged 18 years and above without consideration of gender were selected purposefully. Every patient was evaluated by clinical examination, appropriate investigations and after a confirm diagnosis of the tissue from the cancer. All patients have undergone operative intervention and Gastrectomy specimens were subtotal (including cardiac and pylorus), subtotal (including the pylorus), total radical gastrectomy and oesophago-gastrectomy sample. All specimens obtained were immersed in 10% formalin. Samples of whom were sent to the department of pathology, DMCH for histopathology examination. Portion of representative tissue/block was sent to AFIP (Armed Forces Institute of Pathology, Dhaka) for immunohistochemistry to find out the HER2 expression in gastric cancer and gastro-oesophageal cancer. Data was collected in a pre-designed questionnaire by face to face interview. Result and observation: In this study when 45 cases were categorized according to WHO grading system it was observed that majority (30) patients were found in grade II, among them 3(10%) were HER2 positive. But with grade III tumour the HER2 positivity were found more i,e; 37.5% (3/8). Grade- I tumor show HER2 neu expression 28.57% (2/7) and according to location most of the cases with HER2 positive expression was located in the gastro-esophageal junction which is 27.27% (3/11) than gastric carcinoma which is 14.70% (5/34). Conclusion: Most of the patients of gastric and gastrooesophageal junction adenocarcinoma are diagnosed at a very late stage, so they require special attention in treatment protocol, including chemotherapy and immunotherapy for increasing their survivability. The study showed with poorly differentiated (high grade) tumour, the HER2 positivity were found more. Journal of Surgical Sciences (2018) Vol. 22 (2) : 79-82

Sign in / Sign up

Export Citation Format

Share Document